PMID- 34646438
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220427
IS  - 2042-0188 (Print)
IS  - 2042-0196 (Electronic)
IS  - 2042-0188 (Linking)
VI  - 12
DP  - 2021
TI  - Alteration of serum neuregulin 4 and neuregulin 1 in gestational diabetes 
      mellitus.
PG  - 20420188211049614
LID - 10.1177/20420188211049614 [doi]
LID - 20420188211049614
AB  - CONTEXT: Neuregulin 4 (Nrg4) and neuregulin 1 (Nrg1) have been shown to play 
      vital roles in several disorders of glucose metabolism. The pathophysiological 
      role of Nrg4 and Nrg1 in gestational diabetes mellitus (GDM), however, remains 
      poorly understood. We assessed the clinical relevance of the two cytokines in 
      patients with GDM. METHODS: The study recruited 36 GDM patients and 38 
      age-matched, gestational age (24-28 weeks of gestation)-matched, and BMI (during 
      pregnancy)-matched controls in this study. Serum Nrg4 and Nrg1 were measured 
      using ELISA. Inflammatory factors such as IL-6, IL-1beta, leptin, TNF-alpha, and 
      monocyte chemotactic protein 1 (MCP-1) were determined via Luminex technique. 
      RESULTS: Serum Nrg4 in GDM patients was significantly lower than that in the 
      controls, while Nrg1 was significantly higher in the GDM group (p < 0.01). 
      Inflammatory factors such as IL-6, leptin, and TNF-alpha were significantly increased 
      in GDM patients, while MCP-1 and IL-1beta were not significantly different between 
      the two groups. In addition, serum Nrg4 was negatively correlated with fasting 
      glucose (r = -0.438, p = 0.008), HOMA-IR (r = -0.364, p = 0.029), IL-6 
      (r = -0.384, p = 0.021), leptin (r = -0.393, p = 0.018), TNF-alpha (r = -0.346, 
      p = 0.039), and MCP-1 (r = -0.342, p = 0.041), and positively correlated with 
      high-density lipoprotein cholesterol (HDL-C) (r = -0.357, p = 0.033) in GDM 
      group. Serum Nrg1 was positively correlated with BMI (r = 0.452, p = 0.006), 
      fasting glucose (r = 0.424, p = 0.010), HOMA-IR (r = 0.369, p = 0.027), and 
      triglyceride (r = 0.439, p = 0.007). The decrease of Nrg4 and the increase of 
      Nrg1 were significantly related to the increased prevalence of GDM. Finally, ROC 
      curve results indicated that Nrg1 combined with IL-6 and TNF-alpha might be an 
      effective means for GDM screening. CONCLUSIONS: Lower circulating Nrg4 and higher 
      circulating Nrg1 serve risk factors of GDM. Nrg1 combined with IL-6 and TNF-alpha 
      might be a potential tool for GDM screening.
CI  - (c) The Author(s), 2021.
FAU - Zhang, Lei
AU  - Zhang L
AUID- ORCID: 0000-0001-9640-711X
AD  - Department of Endocrinology and Metabolism, Binzhou Medical University Hospital, 
      Binzhou, China.
FAU - Lu, Bi
AU  - Lu B
AD  - Department of Rheumatology and Endocrinology, Affiliated Aoyang Hospital of 
      Jiangsu University, Suzhou, China.
FAU - Wang, Wenhua
AU  - Wang W
AD  - Department of Neurology, Wuhan Fourth Hospital, Pu-Ai Hospital, Tongji Medical 
      College, Huazhong University of Science and Technology, Wuhan, China.
FAU - Miao, Shifeng
AU  - Miao S
AD  - Department of Cardiology, Affiliated Aoyang Hospital of Jiangsu University, 
      Suzhou, China.
FAU - Zhou, Shuru
AU  - Zhou S
AD  - Aoyang Cancer Institute, Affiliated Aoyang Hospital of Jiangsu University, 
      Suzhou, China.
FAU - Cheng, Xingbo
AU  - Cheng X
AD  - Department of Endocrinology and Metabolism, The First Affiliated Hospital of 
      Soochow University, Suzhou, China.
FAU - Zhu, Jie
AU  - Zhu J
AD  - Department of Cardiology, Affiliated Aoyang Hospital of Jiangsu University, 
      Suzhou, China.
FAU - Liu, Changmei
AU  - Liu C
AD  - Department of Endocrinology and Metabolism, Binzhou Medical University Hospital, 
      Binzhou 256600, Shandong, China.
LA  - eng
PT  - Journal Article
DEP - 20211008
PL  - United States
TA  - Ther Adv Endocrinol Metab
JT  - Therapeutic advances in endocrinology and metabolism
JID - 101532143
PMC - PMC8504227
OTO - NOTNLM
OT  - gestational diabetes mellitus
OT  - inflammation
OT  - insulin resistance
OT  - neuregulin 1
OT  - neuregulin 4
OT  - obesity
COIS- Conflict of interest statement: The authors declared no potential conflicts of 
      interest with respect to the research, authorship, and/or publication of this 
      article.
EDAT- 2021/10/15 06:00
MHDA- 2021/10/15 06:01
PMCR- 2021/10/08
CRDT- 2021/10/14 06:36
PHST- 2021/03/02 00:00 [received]
PHST- 2021/09/12 00:00 [accepted]
PHST- 2021/10/14 06:36 [entrez]
PHST- 2021/10/15 06:00 [pubmed]
PHST- 2021/10/15 06:01 [medline]
PHST- 2021/10/08 00:00 [pmc-release]
AID - 10.1177_20420188211049614 [pii]
AID - 10.1177/20420188211049614 [doi]
PST - epublish
SO  - Ther Adv Endocrinol Metab. 2021 Oct 8;12:20420188211049614. doi: 
      10.1177/20420188211049614. eCollection 2021.